Non-inferiority was shown [ LS mean ( 95 % CI ) HbA1c treatment difference -0.21 ( -0.38 , -0.04 ) ( PP population ) ] ; gated superiority assessment showed a statistically significant advantage for LM25 ( p = 0.010 ; ITT population ) .